Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? - PubMed (original) (raw)
. 2006 Oct;70(8):1486-94.
doi: 10.1038/sj.ki.5001788. Epub 2006 Aug 30.
Affiliations
- PMID: 16941023
- DOI: 10.1038/sj.ki.5001788
Free article
Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
I Bhan et al. Kidney Int. 2006 Oct.
Free article
Abstract
Hypophosphatemia is a common complication of kidney transplantation. Tertiary hyperparathyroidism has long been thought to be the etiology, but hypophosphatemia can occur despite low parathyroid hormone (PTH) levels and can persist after high PTH levels normalize. Furthermore, even in the setting of normal allograft function, hypophosphatemia, and hyperparathyroidism, calcitriol levels remain inappropriately low following transplantation, suggesting that mechanisms other than PTH contribute. Fibroblast growth factor-23 (FGF-23) induces phosphaturia, inhibits calcitriol synthesis, and accumulates in chronic kidney disease. We performed a prospective, longitudinal study of 27 living donor transplant recipients to test the hypotheses that excessive FGF-23 accounts for hypophosphatemia and decreased calcitriol levels following kidney transplantation. Hypophosphatemia <2.5 mg/dl developed in 85% of subjects, including one who had previously undergone parathyroidectomy; 37% developed phosphate < or =1.5 mg/dl. The mean pre-transplant FGF-23 level was 1,218+/-542 RU/ml. Within the first week following transplantation, mean levels decreased to 557+/-579 RU/ml, which were still above normal. FGF-23 was independently associated with serum phosphate (P < 0.01), urinary excretion of phosphate (P < 0.01), and calcitriol levels (P < 0.01); PTH was not independently associated with any of these parameters. We calculated area under the curve for FGF-23 and PTH between the pre- and first post-transplant levels as a summary measure of early exposure to these phosphaturic hormones. An area under the FGF-23 curve greater than the median was associated with a relative risk of developing hypophosphatemia < or =1.5 mg/dl of 5.3 (P = 0.02) compared with lower levels. Increased area under the PTH curve was not associated with greater risk of hypophosphatemia. Excessive FGF-23 exposure in the early post-transplant period appears to be more strongly associated with post-transplant hypophosphatemia than PTH.
Similar articles
- Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.
Han SY, Hwang EA, Park SB, Kim HC, Kim HT. Han SY, et al. Transplant Proc. 2012 Apr;44(3):657-60. doi: 10.1016/j.transproceed.2011.11.046. Transplant Proc. 2012. PMID: 22483462 - Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.
Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Evenepoel P, et al. Am J Transplant. 2007 May;7(5):1193-200. doi: 10.1111/j.1600-6143.2007.01753.x. Epub 2007 Mar 12. Am J Transplant. 2007. PMID: 17359508 Clinical Trial. - Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.
Barros X, Torregrosa JV, Martínez de Osaba MJ, Casals G, Paschoalin R, Durán CE, Campistol JM. Barros X, et al. Transplantation. 2012 Oct 27;94(8):830-6. doi: 10.1097/TP.0b013e318264fc08. Transplantation. 2012. PMID: 23018879 - Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y. Imanishi Y, et al. Ther Apher Dial. 2007 Oct;11 Suppl 1:S32-7. doi: 10.1111/j.1744-9987.2007.00519.x. Ther Apher Dial. 2007. PMID: 17976083 Review. - Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.
Seeherunvong W, Wolf M. Seeherunvong W, et al. Pediatr Transplant. 2011 Feb;15(1):37-46. doi: 10.1111/j.1399-3046.2010.01405.x. Epub 2010 Oct 8. Pediatr Transplant. 2011. PMID: 20946192 Free PMC article. Review.
Cited by
- Bone health and fracture prevention after kidney transplantation.
Jaikaransingh V. Jaikaransingh V. J Clin Transl Endocrinol. 2024 Apr 26;36:100345. doi: 10.1016/j.jcte.2024.100345. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38737624 Free PMC article. Review. - Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia.
Ito N, Hidaka N, Kato H. Ito N, et al. Endocrinol Metab (Seoul). 2024 Apr;39(2):255-261. doi: 10.3803/EnM.2023.1908. Epub 2024 Mar 11. Endocrinol Metab (Seoul). 2024. PMID: 38467164 Free PMC article. Review. - Transplant endocrinology.
Kotwal N, Bansal N, Muthukrishnan J, Verma V. Kotwal N, et al. Med J Armed Forces India. 2023 Nov-Dec;79(6):651-656. doi: 10.1016/j.mjafi.2023.08.017. Epub 2023 Sep 12. Med J Armed Forces India. 2023. PMID: 37981924 Review. - High pretransplant FGF23 level is associated with persistent vitamin D insufficiency and poor graft survival in kidney transplant patients.
Ryu JH, Jeon HJ, Han R, Jung HY, Kim MG, Huh KH, Park JB, Kang KP, Han S, Yang J. Ryu JH, et al. Sci Rep. 2023 Nov 10;13(1):19640. doi: 10.1038/s41598-023-46889-0. Sci Rep. 2023. PMID: 37949967 Free PMC article. - Effect of Intravenous Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation (EFFECT-KTx): rationale and study protocol for a double-blind, randomised, placebo-controlled trial.
Vinke JS, Eisenga MF, Sanders JF, Berger SP, Spikman JM, Abdulahad WH, Bakker SJ, Gaillard CAJM, van Zuilen AD, van der Meer P, de Borst MH. Vinke JS, et al. BMJ Open. 2023 Mar 22;13(3):e065423. doi: 10.1136/bmjopen-2022-065423. BMJ Open. 2023. PMID: 36948568 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical